{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-041308","form_type":"8-K","ticker":"CSBR","cik":"0000771856","company_name":"CHAMPIONS ONCOLOGY, INC.","filed_at":"2023-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.979339+00:00","generated_at":"2026-06-07T14:28:52.753379+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Champions Oncology Q2 revenue $11.6M (-19% YoY); revises FY2024 guidance to flat","bullets":["Operating loss of $2.0M vs $7K income a year ago; adjusted EBITDA loss of $1.4M.","Gross margin fell to 42.8% from 47.9% on lower revenue and fixed costs.","FY2024 revenue guidance revised to be generally flat YoY, citing customer cancellations.","Hired Brady Davis as President to lead new strategic initiatives.","Corellia AI drug discovery advancing with two lead targets; seeking capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-041308","json":"https://secwatch.observer/filing/0001628280-23-041308.json","markdown":"https://secwatch.observer/filing/0001628280-23-041308.md","text":"https://secwatch.observer/filing/0001628280-23-041308.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/771856/000162828023041308/0001628280-23-041308-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/771856/000162828023041308/csbr-20231212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T14:28:52.753379+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8456c4a57482a18ce7e70afc872f78e4280185b3","claim":"CHAMPIONS ONCOLOGY, INC. reported first six months of fiscal 2024 results: revenue $24.1 million.","evidence_excerpt":"For the first six months of fiscal 2024, revenue decreased 13.9% to $24.1 million compared to $28.0 million for the first six months of fiscal 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/771856/000162828023041308/0001628280-23-041308-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first six months of fiscal 2024"},{"label":"Revenue","value":"$24.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"be692e67413e05c0db01c84c432088d3eb00eb3b","claim":"CHAMPIONS ONCOLOGY, INC. reported its second quarter of fiscal 2024, ended October 31, 2023 results: revenue $11.6 million. Guidance lowered.","evidence_excerpt":"Champions Oncology Reports Quarterly Revenue of $11.6 Million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/771856/000162828023041308/0001628280-23-041308-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"its second quarter of fiscal 2024, ended October 31, 2023"},{"label":"Revenue","value":"$11.6 million"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}